143 related articles for article (PubMed ID: 15681899)
1. Functional characterization of single nucleotide polymorphisms with amino acid substitution in CYP1A2, CYP2A6, and CYP2B6 found in the Japanese population.
Iwasaki M; Yoshimura Y; Asahi S; Saito K; Sakai S; Morita S; Takenaka O; Inoda T; Kashiyama E; Aoyama A; Nakabayashi T; Omori S; Kuwabara T; Izumi T; Nakamura K; Takanaka K; Nakayama Y; Takeuchi M; Nakamura H; Kametani S; Terauchi Y; Hashizume T; Nagayama S; Kume T; Achira M; Kawai H; Kawashiro T; Nakamura A; Nakai Y; Kagayama A; Shiraga T; Niwa T; Yoshimura T; Morita J; Ohsawa F; Tani M; Osawa N; Ida K; Noguchi K
Drug Metab Pharmacokinet; 2004 Dec; 19(6):444-52. PubMed ID: 15681899
[TBL] [Abstract][Full Text] [Related]
2. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
Ring HZ; Valdes AM; Nishita DM; Prasad S; Jacob P; Tyndale RF; Swan GE; Benowitz NL
Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205
[TBL] [Abstract][Full Text] [Related]
3. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.
Kimura M; Yamazaki H; Fujieda M; Kiyotani K; Honda G; Saruwatari J; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Dispos; 2005 Sep; 33(9):1361-6. PubMed ID: 15980104
[TBL] [Abstract][Full Text] [Related]
4. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
5. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies.
Kranendonk M; Carreira F; Theisen P; Laires A; Fisher CW; Rueff J; Estabrook RW; Vermeulen NP
Mutat Res; 1999 Apr; 441(1):73-83. PubMed ID: 10224324
[TBL] [Abstract][Full Text] [Related]
6. The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation.
Duarte MP; Palma BB; Gilep AA; Laires A; Oliveira JS; Usanov SA; Rueff J; Kranendonk M
Mutagenesis; 2005 Mar; 20(2):93-100. PubMed ID: 15728263
[TBL] [Abstract][Full Text] [Related]
7. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.
Zhang H; Sridar C; Kenaan C; Amunugama H; Ballou DP; Hollenberg PF
J Pharmacol Exp Ther; 2011 Sep; 338(3):803-9. PubMed ID: 21659470
[TBL] [Abstract][Full Text] [Related]
8. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
Fukami T; Nakajima M; Yoshida R; Tsuchiya Y; Fujiki Y; Katoh M; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2004 Dec; 76(6):519-27. PubMed ID: 15592323
[TBL] [Abstract][Full Text] [Related]
9. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
Heyn H; White RB; Stevens JC
Drug Metab Dispos; 1996 Sep; 24(9):948-54. PubMed ID: 8886603
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of cytochrome P450 2B6 allelic variants.
Jinno H; Tanaka-Kagawa T; Ohno A; Makino Y; Matsushima E; Hanioka N; Ando M
Drug Metab Dispos; 2003 Apr; 31(4):398-403. PubMed ID: 12642465
[TBL] [Abstract][Full Text] [Related]
11. A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation.
Ariyoshi N; Miyazaki M; Toide K; Sawamura Yi ; Kamataki T
Biochem Biophys Res Commun; 2001 Mar; 281(5):1256-60. PubMed ID: 11243870
[TBL] [Abstract][Full Text] [Related]
12. CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions.
Yamanaka H; Nakajima M; Fukami T; Sakai H; Nakamura A; Katoh M; Takamiya M; Aoki Y; Yokoi T
Drug Metab Dispos; 2005 Dec; 33(12):1811-8. PubMed ID: 16135656
[TBL] [Abstract][Full Text] [Related]
13. The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450-mediated biotransformation (a corrigendum report on Duarte et al. (2005) Mutagenesis 20, 93-100).
Duarte MP; Palma BB; Gilep AA; Laires A; Oliveira JS; Usanov SA; Rueff J; Kranendonk M
Mutagenesis; 2007 Jan; 22(1):75-81. PubMed ID: 17158518
[TBL] [Abstract][Full Text] [Related]
14. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.
Kamataki T; Fujita K; Nakayama K; Yamazaki Y; Miyamoto M; Ariyoshi N
Drug Metab Rev; 2002 Aug; 34(3):667-76. PubMed ID: 12214673
[TBL] [Abstract][Full Text] [Related]
15. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; Sakai H; McLeod HL; Yokoi T
Drug Metab Dispos; 2005 Aug; 33(8):1202-10. PubMed ID: 15900015
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma.
Mochizuki J; Murakami S; Sanjo A; Takagi I; Akizuki S; Ohnishi A
J Gastroenterol Hepatol; 2005 Aug; 20(8):1191-7. PubMed ID: 16048566
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of (-)-fenchone by CYP2A6 and CYP2B6 in human liver microsomes.
Miyazawa M; Gyoubu K
Xenobiotica; 2007 Feb; 37(2):194-204. PubMed ID: 17484521
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization of cytochrome P450 2A6 allelic variants CYP2A6*15, CYP2A6*16, CYP2A6*21, and CYP2A6*22.
Tiong KH; Yiap BC; Tan EL; Ismail R; Ong CE
Drug Metab Dispos; 2010 May; 38(5):745-51. PubMed ID: 20139165
[TBL] [Abstract][Full Text] [Related]
20. Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262.
Ariyoshi N; Ohara M; Kaneko M; Afuso S; Kumamoto T; Nakamura H; Ishii I; Ishikawa T; Kitada M
Drug Metab Dispos; 2011 Nov; 39(11):2045-8. PubMed ID: 21821736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
